NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Thyroiditis


Return to Library

Free Thyroiditis Articles


Reports from Zhejiang University, Department of Dermatology describe recent advances in hypersensitivity therapy



2009 JUL 20 - (NewsRx.com) -- New investigation results, 'Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome,' are detailed in a study published in Journal of Clinical Pharmacy & Therapeutics. "Dapsone is still widely used for a range of infectious and inflammatory diseases. A potential severe side-effect, known as dapsone-induced hypersensitivity syndrome (DHS), may occur," scientists in People's Republic of China report.

"DHS is characterized by fever, skin rashes, lymphadenopathy and multiorgan dysfunction manifesting as hepatitis, cholangitis, pneumonitis, colitis, thyroiditis and myocarditis. However, DHS-associated complete atrioventricular block has not previously been reported. We describe here a 45-year-old Chinese woman who developed DHS after 5 weeks of dapsone therapy for pustular palmoplantar psoriasis," wrote K.J. Zhu and colleagues, Zhejiang University, Department of Dermatology.

The researchers concluded: "In addition to typical DHS symptoms, she experienced several episodes of syncope as a result of complete atrioventricular block which was successfully reversed with a permanent pacemaker implantation."

Zhu and colleagues published their study in the Journal of Clinical Pharmacy & Therapeutics (Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome. Journal of Clinical Pharmacy & Therapeutics, 2009;34(4):489-92).

For more information, contact K.J. Zhu, Sir Run Run Shaw Hospital, Dept. of Dermatology, Zhejiang University School of Medicine, Zhejiang, China.

Publisher contact information for the Journal of Clinical Pharmacy & Therapeutics is: Blackwell Publishing Inc., 350 Main St., Malden, MA 02148, USA.

Keywords: People's Republic of China, Hypersensitivity Therapy, Cardiology, Cholangitis, Clinical Pharmacy, Colitis, Dapsone, Dermatology, Drugs, Gastroenterology, Heart Block, Hematology, Hepatitis, Hypersensitivity, Infectious Disease, Lymphadenopathy, Myocarditis, Pharmaceuticals, Pneumonia, Therapy, Thyroiditis, Treatment.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login